Introduction
============

Gastric cancer (GC) is one of the most prevalent malignancies worldwide [@B1]. Despite recent therapeutic advances, the overall prognosis of recurrent or metastatic GC remains dismal, thereby necessitating the unearthing of novel therapeutic targets in GC [@B2]-[@B4].

The invasive and migratory capability of malignant tumor cells into neighboring microenvironment is the most critical step that governs the entire process of tumor progression [@B5], [@B6]. Among the prime mediators which are responsible for tumor cell migration and invasion, one particular family of proteins that seems to play a decisive role is Rho GTPase [@B7]-[@B9]. They are molecular switches which regulate various intracellular processes such as cytoskeletal rearrangement, thereby playing important roles in every aspects of tumor progression including malignant transformation, proliferation, invasion, and metastasis of tumor cells [@B8]-[@B10]. Among more than 20 members of Rho family, RhoA and Rac1 are most extensively studied where their overexpression was found to be closely related to GC progression, while other members are largely uncharted [@B10].

RhoJ is a recently identified member of Rho family [@B11], [@B12]. Although RhoJ shares structural similarities and common effector molecules with other Rho GTPases, it has other distinct characteristics [@B12]-[@B14]. Recently published study demonstrates that RhoJ is enriched in endothelial cells and plays a positive angiogenic role during tumor progression and wound healing [@B15]. However, little is known regarding the role of RhoJ in non-endothelial cells such as tumor cells. Intriguingly, few recent studies have been published regarding the expression of RhoJ in melanoma cells and addressed its role in the regulation of melanoma cell migration and invasion [@B16], [@B17]. Considering these findings, we set out to investigate the possible role of RhoJ during GC progression.

In the present study, we aimed to demonstrate the correlation between RhoJ expression and clinicopathologic parameters as well as to uncover the putative role of RhoJ in regulating GC cell behavior.

Materials and Methods
=====================

Cell culture and transfection
-----------------------------

Human gastric cancer cell lines, YCC-1, YCC-2, YCC-3, YCC-7, YCC-9, YCC-10,YCC-11, and YCC-16 were established by Yonsei Cancer Center (Seoul, Korea) from GC patients through the isolation of blood (YCC-16) or ascites (others cell lines). Cells were incubated in RPMI-1640 (Welgene) with 10% fetal bovine serum (FBS) in 5% CO~2~ at 37°C. Human umbilical vein endothelial cells (HUVEC, Lonza) were cultured in endothelial growth medium (EGM-2, Lonza). Full-length human RhoJ expression vector and an empty vector were acquired from Addgene (<http://addgene.org>). YCC-16 cells were transfected with either the RhoJ expression vector or empty vector by using Lipofectamine LTX (Life Technologies) following the manufacturer\'s instruction.

Western blotting
----------------

Cell lysates were separated with SDS-PAGE and transferred to PVDF membranes (Millipore). The membranes were blocked with 5% skim milk, followed by the incubation with the following primary antibodies: RhoJ (mouse monoclonal, Abnova) and GAPDH (rabbit polyclonal, Santacruz). The bound antibodies were visualized with HRP-conjugated secondary antibodies. Signals were developed with HRP substrate and detected with LAS-1000 (Fuji film).

Proliferation assay
-------------------

The cells were placed in a 96-well plate at a concentration of 5×10^3^ cells per well. After incubation for 1 to 3 days, the amount of viable cells was determined using the water-soluble tetrazolium assay (WST) kit (DaeilLab). After incubating the cells with WST solution for 20 min at 37°C, optical absorbance was measured with a microplate reader (Bio-Rad).

Migration assay
---------------

4×10^4^ cells were seeded in serum-free medium onto the upper chamber of 24-well culture inserts with 8 μm pores (Millipore) and medium containing 5% FBS was placed in the lower chamber. After 24 hr, the cells on the upper surface of membrane were removed with a cotton swab. The cells that had migrated to the lower surface of membrane were fixed and visualized with 1% crystal violet (Sigma).

Invasion assay
--------------

Cell invasion was compared using BioCoat Matrigel^TM^ invasion chambers (BD). 4×10^4^ cells were plated in the upper chamber in serum-free medium and the lower chamber was filled with medium containing 10% FBS. After 36 hours, the cells on the upper surface were removed with a cotton swab. The cells that had migrated through the Matrigel^TM^ invasion chamber were fixed and visualized with 1% crystal violet.

Patients and surgical specimens
-------------------------------

70 patients who were diagnosed with primary gastric adenocarcinoma and received radical gastrectomy were enrolled at Yonsei Cancer Center, Severance Hospital (Yonsei University Health System, Seoul, Korea). The clinicopathologic variables including age, sex, histologic type, Lauren\'s classification, stage, type of surgery, and survival outcome were reviewed retrospectively based on the electronic medical records. Pathological diagnosis and staging of GC was made according to the American Joint Committee on Cancer 2010 staging system. The study was approved by the institutional review board.

Immunohistochemical and immunofluorescent staining
--------------------------------------------------

Immunohistochemical (IHC) staining was performed on the surgical specimens of GC patients. Slides were antigen-retrieved by autoclaving and blocked. Samples were incubated with RhoJ antibody (mouse monoclonal clone 1E4, Abnova) overnight, followed by incubation with biotinyated secondary antibody. Slides were reacted with Vectastatin ABC reagent (Vector laboratories) and DAB (DAKO) was used as a chromogen. The following scoring system was used to grade RhoJ immunoreactivity: score 0 = no staining or non-specific staining of tumor cells; score 1 = weak and incomplete staining of \>10% of tumor cells; score 2 = moderate and complete staining of \>33% of tumor cells; score 3 = strong and complete staining of \>67% of tumor cells. Those with \>10% positive stained tumor cells (scores 1 to 3) were regarded to be RhoJ-positive. RhoJ immunoreactivity in endothelial cells was excluded from analysis. For immunofluorescent (IF) staining, cells cultured on coverslips were blocked and incubated overnight with the phospho-histone H3 antibody (Cell Signaling). Then, slides were incubated with cy3-conjugated secondary antibodies (Jackson ImmunoResearch). Nuclei were stained with DAPI (Invitrogen) and F-actin was stained with Acti-stain Phalloidin (Cytoskeleton). Then the slides were mounted and imaged with a LSM510 confocal microscope (Carl Zeiss).

Statistical analysis
--------------------

Survival curves were estimated with the Kaplan-Meier method, and the statistical differences were determined using the log-rank test. Overall survival (OS) was calculated from the date of gastrectomy to the date of death, while recurrence-free survival (RFS) was defined as the interval between the date of gastrectomy and the date of either recurrence or death. Multivariate analyses were performed with the Cox proportional hazard model. Chi-square tests and independent sample t-test were used for the analysis of variables. All statistical analyses were carried out with SPSS version 12.0 (SPSS, Inc.).

Results
=======

Human GC cell lines express RhoJ differently
--------------------------------------------

At first, we compared the expression of RhoJ proteins in various human GC cell lines and HUVECs using immunoblotting. The expression levels of RhoJ differed among different GC cell lines, with the highest in YCC-9 cell line, in which the expression level of RhoJ was higher than that of human endothelial cell, HUVEC, while being barely detectable in YCC-10, -11, and -16 cell lines (Figure [1](#F1){ref-type="fig"}A). These findings suggest that human GC cells also express RhoJ as well as endothelial cells.

High RhoJ expression is associated with diffuse type GC at later stages and poor survival outcome as well as more frequent distant metastasis
---------------------------------------------------------------------------------------------------------------------------------------------

To evaluate the expression of RhoJ in GC tissues in addition to the cell lines, we performed IHC staining for 70 cases of surgically resected GC specimens. IHC staining results displayed RhoJ expression in GC tissues with varied intensities (Figure [1](#F1){ref-type="fig"}B). When the intensity of RhoJ expression was graded as negative (≤10% of cells stained) or positive (\>10% of cells stained), of the 70 GC tumor specimens, 34 (48.6%) displayed the expression of RhoJ, while 36 (51.4%) did not show any expression of RhoJ. We were able to observe the strong expression of RhoJ in cytoplasm of tumor cells, while it was occasionally expressed in tumor vasculatures (Figure [1](#F1){ref-type="fig"}C).

The baseline characteristics of the patient cohort are summarized in Table [1](#T1){ref-type="table"}. The median age at the time of GC diagnosis was 62 years (range 33-83) and the male-to-female ratio was 1.9. The most common histologic type was tubular adenocarcinoma (70%) and 57.1% of tumors were classified as diffuse type by Lauren\'s classification. Almost all patients (94.3%) received adjuvant chemotherapy, while only 2 out of 70 patients (2.9%) underwent adjuvant radiotherapy. The median follow-up duration was 47.5 months and 47.1% of patients were alive at the time of analysis.

To characterize the features of GC patients with RhoJ expression, various clinicopathologic parameters were compared according to the RhoJ expressing status (Table [2](#T2){ref-type="table"}). Patients with RhoJ-positive tumors had more diffuse type GC (73.5% vs. 41.7%, p=0.007) at later stages (stage III, IV: 85.3% vs. 58.4%, p=0.023) and distant metastasis (47.1% vs. 11.1%, p=0.001), denoting that RhoJ has a positive role in tumor progression and metastasis. In addition, RhoJ-positive tumors tended to be more poorly differentiated adenocarcinoma and signet ring cell carcinoma compared to RhoJ-negative tumors (82.4% vs. 52.8%, p=0.043). However, there were no significant differences in age, sex, T stage, and N stage between RhoJ-positive and RhoJ-negative GC patients. Moreover, the proportion of patients receiving adjuvant chemotherapy or radiotherapy was not different between RhoJ-negative and RhoJ-positive groups.

High RhoJ expression is associated with poor survival outcome in GC patients
----------------------------------------------------------------------------

On Kaplan-Meier survival analysis, RhoJ-positive group displayed markedly poorer OS and RFS compared with RhoJ-negative group (p=0.001 and 0.002, respectively) (Figure [2](#F2){ref-type="fig"}A and 2B).

Next, we further examined the prognostic value of high RhoJ expression with adjustments for other prognostic factors with a Cox\'s multivariate analysis (Table [3](#T3){ref-type="table"}). Even after the adjustment, high RhoJ expression still conferred a significant impact on OS and RFS of GC patients (p=0.038 and p=0.047, respectively), indicating that it is an independent prognostic factor for OS and RFS. Collectively, these findings evidence that high RhoJ expression is a negative prognostic factor for the survival outcome of GC patients.

RhoJ overexpression enhanced GC cell migration and invasion in vitro
--------------------------------------------------------------------

To elucidate the role of RhoJ overexpression on the biologic behavior of GC cells, we established RhoJ-overexpressing (RhoJ-OV) cells by transfecting YCC-16 GC cell lines with RhoJ-expressing plasmid (Figure [3](#F3){ref-type="fig"}A). The overexpression of RhoJ in RhoJ-OV cells did not affect the proliferation of GC cells compared to empty-vector transfected control (RhoJ-WT) cells (Figure [3](#F3){ref-type="fig"}B). In addition, there was no difference in the proportion of PH3^+^ proliferating cells between RhoJ-OV and RhoJ-WT cells (Figures [3](#F3){ref-type="fig"}C and 3D), indicating that RhoJ has negligible role in the regulation of GC cell proliferation. On the other hand, RhoJ-OV cells displayed 41.3% increase in cell motility across the membrane of cell culture inserts (p=0.015) (Figures [3](#F3){ref-type="fig"}E and 3F). Moreover, RhoJ-OV cells had 60.4% enhanced invasion ability across the Matrigel^TM^ extracellular matrix compared to RhoJ-WT cells (p=0.024) (Figures [3](#F3){ref-type="fig"}G and 3H). Taking these results together, we were able to confirm that RhoJ in GC cell plays an important role in the regulation of GC cell motility and invasiveness.

Discussion
==========

Rho GTPases regulate diverse cellular processes such as cytoskeletal rearrangement, cell motility, cell-cycle progression, and transcription [@B9],[@B10]. Though there are increasing number of preclinical evidences reporting the importance of Rho GTPases during tumor progression and metastasis [@B8]-[@B10], the clinical significance of Rho GTPases in human cancer is largely unknown, especially in GC. Only few studies reported increased expression of RhoA, RhoC, and Rac1 in GC and their prognostic role in GC [@B10],[@B18],[@B19].

Inspired by these recent results in the role of RhoJ in melanoma [@B16],[@B17], we explored whether RhoJ is also expressed in GC tissue. Intriguingly, in human GC, RhoJ was predominantly expressed in tumor cells with occasional expression in some part of tumor vasculatures. This finding implies that the cells responsible for RhoJ expression may vary according to the types of cancer. In GC, RhoJ expression in tumor cells seems to be more prevailing compared to endothelial RhoJ expression. Moreover, we examined whether RhoJ expression has a potential clinical value in GC patients. As a result, we were able to confirm the varied expression of RhoJ in GC cell lines and GC tissues, and could demonstrate that high RhoJ expression is a negative prognostic factor for the OS and RFS of GC patients after curative surgery. Even after adjustment for other prognostic factors, high RhoJ expression had significantly negative influence on survival outcome of GC patients. To our knowledge, this is the first study to demonstrate the independent prognostic value of RhoJ in human cancer.

We were also able to discover the possible mechanism in which RhoJ leads to the progression and metastasis of GC. Our in vitro experiments displayed the increased motility and invasiveness of GC cells where RhoJ was forcefully overexpressed by the transfection of RhoJ-expression vector compared to control GC cells, while there was no difference in terms of GC cell proliferation. This in vitro evidence suggests that the increased progression and metastasis observed in RhoJ-high GC patients might be attributed to the enhanced migratory and invasive ability of highly RhoJ-expressing GC cells.

Despite the novel findings of our study, one critical question that remained to be answered in the future is whether RhoJ is a feasible therapeutic target for the treatment of GC. For the moment, there is no direct evidence indicating the therapeutic value of RhoJ blockade in human cancer. However, previous studies employing animal tumor models could provide some hints to this question. The previous work that focused on endothelial RhoJ showed that the genetic deletion of host-derived RhoJ could suppress tumor progression and metastasis through the inhibition of tumor angiogenesis [@B15]. Besides, Ho et al. reported that the knockdown of RhoJ in melanoma cell with shRNA could delay melanoma growth and lymphatic metastasis [@B17]. Therefore, the strategy of targeting RhoJ has the potential of dual-targeting of tumor cells and tumor vessels simultaneously. This hypothesis has to be validated with animal models of GC when RhoJ inhibitors are developed and become available.

In conclusion, the current study presents evidence that RhoJ is positively associated with the regulation of tumor cell motility and invasiveness in GC. Moreover, we were able to demonstrate that high RhoJ expression in GC is an independent negative prognostic factor after gastrectomy. Further studies are required to validate the therapeutic role of RhoJ in GC by using RhoJ-specific inhibitor.
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![**RhoJ expression in GC cell lines and surgical specimens of GC patients.**(A) Various GC cell lines and HUVECs were cultured for 24 hr and harvested. Immunoblotting showing differential levels of RhoJ expression in various GC cell lines and HUVEC. EC, endothelial cell. (B) Immunohistochemical staining showing RhoJ expression in GC tissue. Scale bar: 200 μm. (C) Endothelial expression of RhoJ in GC tissue. Arrows indicate the endothelial expression of RhoJ. Scale bar: 200 μm.](jcav07p1550g001){#F1}

![**RhoJ expression is a negative prognostic factor for GC patients.**(A) Kaplan-Meier analysis of overall survival (OS) in RhoJ-positive and RhoJ-negative GC patients. (B) Kaplan-Meier analysis of recurrence-free survival (RFS) in RhoJ-positive and RhoJ-negative GC patients.](jcav07p1550g002){#F2}

![**RhoJ-overexpressing GC cells have enhanced migratory and invasion ability.**YCC-16 cells were transfected with either empty or RhoJ-expressing vectors using Lipofectamine. Unless otherwise denoted: Values are mean ± standard deviations. n=5. \*p\<0.05 versus RhoJ-WT. (A) RhoJ expression level was compared by immunoblotting 24 hr after transfection. RhoJ-overexpressing (RhoJ-OV) cells displayed markedly increased RhoJ expression compared to control (RhoJ-WT) cells. (B) The effect of RhoJ expression on GC cell proliferation. Cell viability was evaluated using WST assay on the indicated time points after transfection. (C and D) Images and quantification of PH3^+^ proliferating cells. (E and F) Images and quantification of GC cell migration across cell culture insert after 24 hr of incubation. (G and H) Images and quantification of GC cell invasion across Matrigel extracellular matrix after 36 hr of incubation.](jcav07p1550g003){#F3}

###### 

Baseline characteristics of the cohort.

                              N (%) (n=70)
  --------------------------- --------------
  **Age** (median, range)     62 (33-83)
  **Sex**                     
  Male                        46 (65.7)
  Female                      24 (34.3)
  **Histology**               
  WD                          3 (4.3)
  MD                          17 (24.3)
  PD                          29 (41.4)
  SRC                         18 (25.7)
  Others                      3 (4.3)
  **Lauren classification**   
  Intestinal                  30 (42.9)
  Diffuse                     40 (57.1)
  **Stage**                   
  IIA                         10 (14.3)
  IIB                         10 (14.3)
  IIIA                        4 (5.7)
  IIIB                        8 (11.4)
  IIIC                        18 (25.7)
  IV                          20 (28.6)
  **Type of surgery**         
  Total gastrectomy           36 (51.4)
  Subtotal gastrectomy        34 (48.6)
  **Adjuvant therapy**        
  Adjuvant chemotherapy       66 (94.3)
  Adjuvant radiotherapy       2 (2.9%)

WD, well differentiated; MD, moderately differentiated;

PD, poorly differentiated; SRC, signet ring cell.

###### 

Correlation between RhoJ expression and clinical parameters.

                              RhoJ-negative (n=36)   RhoJ-positive (n=34)   p-value
  --------------------------- ---------------------- ---------------------- ---------
  **Age**                     61 (33-76)             59 (33-83)             0.865
  **Sex**                                                                   0.863
  Male                        24 (66.7)              22 (64.7)              
  Female                      12 (33.3)              12 (35.3)              
  **Histology**                                                             0.043
  WD and MD                   15 (41.7)              5 (14.7)               
  PD and SRC                  19 (52.8)              28 (82.4)              
  Others                      2 (5.5)                1 (2.9)                
  **Lauren classification**                                                 0.007
  Intestinal                  21 (58.3)              9 (26.5)               
  Diffuse                     15 (41.7)              25 (73.5)              
  **Stage**                                                                 0.023
  IIA                         7 (19.4)               3 (8.8)                
  IIB                         8 (22.2)               2 (5.9)                
  IIIA                        2 (5.6)                2 (5.9)                
  IIIB                        5 (13.9)               3 (8.8)                
  IIIC                        10 (27.8)              8 (23.5)               
  IV                          4 (11.1)               16 (47.1)              
  **T stage**                                                               0.411
  T2                          4 (11.1)               4 (11.8)               
  T3                          10 (27.8)              4 (11.8)               
  T4a                         19 (52.8)              22 (64.7)              
  T4b                         3 (8.3)                4 (11.8)               
  **N stage**                                                               0.467
  N0                          8 (22.2)               3 (8.8)                
  N1                          9 (25.0)               7 (20.6)               
  N2                          4 (11.1)               6 (17.6)               
  N3a                         13 (36.1)              14 (41.2)              
  N3b                         2 (5.6)                4 (11.8)               
  **M stage**                                                               0.001
  M0                          32 (88.9)              18 (52.9)              
  M1                          4 (11.1)               16 (47.1)              

###### 

Prognostic factor for OS and RFS in multivariate Cox regression model.

                                   OS                         RFS                
  -------------------------------- ------------------ ------- ------------------ -------
  Age (≥65 vs. \<65)               0.70 (0.35-1.41)   0.314   0.39 (0.18-0.85)   0.018
  RhoJ (Positive vs. Negative)     2.68 (1.30-5.53)   0.038   2.09 (1.01-4.32)   0.047
  Histology (PD, SRC vs. WD, MD)   1.44 (0.72-2.88)   0.302   1.56 (0.78-3.12)   0.213
  Stage (III, IV vs. II)           2.74 (1.13-6.65)   0.025   3.03 (1.13-8.11)   0.027
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